What is VRXA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.15B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VRXA?

P/E (TTM) is n/a and 52-week range is $0.99 to $27.36 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VRXA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

Where is Veraxa Biotech AG based, and what identifiers does Chartloom list?

The company context section lists headquarters in Zurich, Zuerich, CH, 141.4M shares outstanding, ISIN CH1476899161 when available from company profile and filing metadata.

Veraxa Biotech AG

$VRXA

Health Care · Biotechnology

Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

Veraxa Biotech AG

$VRXA

Health Care · Biotechnology

Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Veraxa Biotech AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Zurich, Zuerich. The company went IPO on 2026-06-11. Veraxa Biotech AG is a Switzerland-based Company that develops antibody-based therapeutics for the treatment of cancer. The firm focuses on advancing proprietary platform technologies designed to generate targeted oncology therapies with improved safety and efficacy profiles. Its approach originates from scientific discoveries at the European Molecular Biology Laboratory, supporting the development of next-generation antibody-based drug candidates. The firm aims to expand treatment options for solid tumors by enabling more precise targeting mechanisms and potentially broader therapeutic windows compared with conventional therapies, addressing unmet needs across oncology markets through platform-driven innovation.

IPO

2026-06-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

CH1476899161

Headquarters

Zurich, Zuerich, CH

Shares outstanding

141.4M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

2.02%

Browse other companiesFree AI scores and summaries for more stocks

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Veraxa Biotech AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Zurich, Zuerich. The company went IPO on 2026-06-11. Veraxa Biotech AG is a Switzerland-based Company that develops antibody-based therapeutics for the treatment of cancer. The firm focuses on advancing proprietary platform technologies designed to generate targeted oncology therapies with improved safety and efficacy profiles. Its approach originates from scientific discoveries at the European Molecular Biology Laboratory, supporting the development of next-generation antibody-based drug candidates. The firm aims to expand treatment options for solid tumors by enabling more precise targeting mechanisms and potentially broader therapeutic windows compared with conventional therapies, addressing unmet needs across oncology markets through platform-driven innovation.

IPO

2026-06-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)